Physician profile
Stuart I Kaplan
NPI 1790776219
$8,616.83
in general payments reported to CMS, 2019-2025
26 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $482 · 2021: $1,280 · 2022: $915 · 2023: $1,214 · 2024: $1,335 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,755 · Entertainment: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,755.00 |
| Entertainment | $116.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,000.53 | 2019-2025 | Total30, Precision7, Tryptyr |
| Bausch & Lomb Americas INC. | $983.35 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $700.65 | 2019-2021 | |
| Biotissue Holdings INC. | $645.15 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $544.20 | 2019-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $515.75 | 2024-2025 | Xdemvy |
| Optos, INC. | $428.85 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $382.48 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Allergan, INC. | $380.61 | 2020-2022 | |
| Dompe US, INC. | $347.40 | 2021-2024 | Oxervate |
| Glaukos Corporation | $330.37 | 2025 | Idosetr, Istent Infinite |
| Abbvie INC. | $251.70 | 2022-2025 | |
| Ocular Therapeutix, INC. | $223.80 | 2019-2024 | Dextenza |
| Optovue, INC. | $178.39 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $153.55 | 2025 | Acuvue |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $100.38 | 2022 | |
| Lkc Technologies, INC. | $88.46 | 2025 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $67.88 | 2021-2023 | |
| Kala Pharmaceuticals, INC. | $61.75 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $39.27 | 2019 | |
| Visionix USA, INC | $35.18 | 2022 | |
| Harrow Eye, LLC | $21.15 | 2025 | Vevye |
| Astellas Pharma US INC | $18.51 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $18.08 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.